Citation Impact
Citing Papers
Carotenoids: biochemistry, pharmacology and treatment
2016 Standout
Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult
2002 Standout
Dative P→Sn interactions in ortho-phenylene phosphine-stannanes
2010
Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
2008
Effects of the Antifungal Agents on Oxidative Drug Metabolism
2000
Role of alterations in ca2+‐associated signaling pathways in the immunotoxicity of polycyclic aromatic hydrocarbons
1995
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent
2011
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
2005
Treatment Strategies Targeting Amyloid -Protein
2012
Advances in the design and synthesis of prazosin derivatives over the last ten years
2011
Mechanisms of idiosyncratic drug reactions: the case of felbamate
2002
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Alzheimer's disease
2011 Standout
Pharmacokinetic interactions between herbal remedies and medicinal drugs
2002
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
2002
Clinical Pharmacology of New Histamiine H1 Receptor Antagonists
1999
Highly Enantioselective Synthesis of 3‐Substituted Furanones by Palladium‐Catalyzed Kinetic Resolution of Unsymmetrical Allyl Acetates
2012 StandoutNobel
Levetiracetam: A Novel Antiepileptic Drug
2001
HLA-B*5701 Screening for Hypersensitivity to Abacavir
2008 Standout
Physiology-Based Simulations of a Pathological Condition
2008
Preclinical safety testing of biotechnology-derived pharmaceuticals
2004
Immune attack: the role of inflammation in Alzheimer disease
2015 Standout
Pharmacokinetics of Haloperidol
1989
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
2019 Standout
Store-Operated Calcium Channels
2005 Standout
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Cell death assays for drug discovery
2011
The carcinogenicity of dichloroacetic acid in the male fischer 344 rat
1996
Protein aggregation diseases: pathogenicity and therapeutic perspectives
2010
Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles
2004
Metal‐Catalyzed Enantioselective Allylation in Asymmetric Synthesis
2007 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
Aqueous date fruit extract protects against lipid peroxidation and improves antioxidant status in the liver of rats subchronically exposed to trichloroacetic acid
2014
Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals
2007
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>
2009
Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver
2008
Pharmacokinetics of Haloperidol
1999
CYP2B6983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment
2007
FAILURE OF MONOCHLOROACETIC ACID AND TRICHLOROACETIC ACID ADMINISTERED IN THE DRINKING WATER TO PRODUCE LIVER CANCER IN MALE F344/N RATS
1997
The Amyloid State of Proteins in Human Diseases
2012 Standout
Relating protein pharmacology by ligand chemistry
2007 Standout
Species differences in the structure and function of the immune system
2003
Alzheimer's disease: strategies for disease modification
2010
Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases
2008 Standout
REGULATION OF CYP2B6 IN PRIMARY HUMAN HEPATOCYTES BY PROTOTYPICAL INDUCERS
2004
Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population
2009
Glycocalyx Engineering with a Recycling Glycopolymer that Increases Cell Survival In Vivo
2015 StandoutNobel
Herb-Drug Interactions
2005 Standout
A Novel Distal Enhancer Module Regulated by Pregnane X Receptor/Constitutive Androstane Receptor Is Essential for the Maximal Induction of CYP2B6 Gene Expression
2003
Occurrence, genotoxicity, and carcinogenicity of regulated and emerging disinfection by-products in drinking water: A review and roadmap for research
2007 Standout
Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries
2009
CURCUMIN: THE INDIAN SOLID GOLD
2007 Standout
Platinum Group Organometallics Based on “Pincer” Complexes: Sensors, Switches, and Catalysts
2001 Standout
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
2011 Standout
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring
2014 StandoutNobel
Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 Inducers
2006
The projected effect of risk factor reduction on Alzheimer's disease prevalence
2011 Standout
Frustrated Lewis Pair Chemistry: Development and Perspectives
2015 Standout
The amyloid state and its association with protein misfolding diseases
2014 Standout
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
Dietary Curcumin Enhances Antibody Response in Rats
1997
Curcumin: From ancient medicine to current clinical trials
2008 Standout
Natural products against cancer angiogenesis
2016
The pharmacogenetics of antiretroviral therapy
2006
The amyloid hypothesis of Alzheimer's disease at 25 years
2016 Standout
A Mechanistic Approach to Antiepileptic Drug Interactions
1998
Intramembrane Proteolysis
2009
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
2020 Standout
Chiral 1,1-diaryl compounds as important pharmacophores
2013
Alzheimer's disease
2017 Standout
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
Chiral aminophosphonite-phosphite ligands: synthesis and use in platinum- and rhodium-based enantioselective hydroformylation of styrene. Crystal structure of [(S)-N-(2,2′biphenoxyphosphino)-2-(2,2′biphenoxyphosphinoxymethyl)pyrrolidine]dichloroplatinum(II)
2001
Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition
2003
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
A Novel Chiral Phosphino−Phosphaferrocene: Its Coordination Behavior and Application to Palladium-Catalyzed Asymmetric Allylic Alkylation
2001
Worldwide Variation in Human Drug-Metabolism Enzyme GenesCYP2B6andUGT2B7: Implications for HIV/AIDS Treatment
2012
Influence of Liver Fibrosis Stage on Plasma Levels of Antiretroviral Drugs in HIV‐Infected Patients with Chronic Hepatitis C
2007
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
Of Mice and Not Men: Differences between Mouse and Human Immunology
2004 Standout
Chiral Diarylmethanes via Copper-Catalyzed Asymmetric Allylic Arylation with Organolithium Compounds
2015 StandoutNobel
Pharmacokinetic Interactions of Drugs with St John’s Wort
2004
Robust Ligand-Based Modeling of the Biological Targets of Known Drugs
2006
The Role of Oxidative Stress and Antioxidants in Liver Diseases
2015 Standout
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
2014
Aromatic Trifluoromethylation with Metal Complexes
2011 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Platinum-195 nuclear magnetic resonance
1982
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
2004
Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
2006 Standout
Disease-modifying treatments for Alzheimer’s disease
2011
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
The trans-influence: its measurement and significance
1973 Standout
Triethyl phosphite as a ligand on ruthenium(II)
1978 StandoutNobel
Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes
2004 Standout
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda
2007
PolymorphicCYP2B6: Molecular Mechanisms and Emerging Clinical Significance
2007
Applied Hydroformylation
2012 Standout
Prescribed drugs containing nitrogen heterocycles: an overview
2020 Standout
Works of Gary Mather being referenced
In Vitro Evaluation of Potential Drug Interactions With Levetiracetam, A New Antiepileptic Agent
1999
Alterations of rat natural killer (NK) cell cytotoxicity and cytokine production by 3-methylcholanthrene (3-MC)
1990
Nefopam enantiomers: Preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration
2000
Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals
2007
Characterization of a Chemically Induced Tumor Model and the Effects of Natural Killer Cell Depletion by Antiasialo GM-1
1994
Lack of Effect of Azelastine and Ketoconazole Coadministration on Electrocardiographic Parameters in Healthy Volunteers
1997
Subchronic 90 day toxicity of dichloroacetic and trichloroacetic acid in rats
1990
Immunotoxicity testing in the rat: An improved multiple assay model
1990
Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants*
1997
Pharmacokinetic Interactions with Felbamate
1997
X-Ray crystal structure analysis, nuclear magnetic resonance and Mössbauer parameters of trans-tetrachlorobis(triethylphosphine)tin(IV )
1973
Interpretation of tungsten-183–phosphorus-31 nuclear spin coupling constants
1970
Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer
2010
Characterization of the In Vitro Biotransformation of the HIV-1 Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450
1999
Correlation of nuclear magnetic resonance coupling constants with transition metal–ligand bond lengths in tertiary phosphine complexes
1973
Discovery of 2-Chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a Potent Inducer of Apoptosis with High In Vivo Activity
2008